These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30071865)

  • 1. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
    Diamond JR; Eckhardt SG; Pitts TM; van Bokhoven A; Aisner D; Gustafson DL; Capasso A; Sams S; Kabos P; Zolman K; Colvin T; Elias AD; Storniolo AM; Schneider BP; Gao D; Tentler JJ; Borges VF; Miller KD
    Breast Cancer Res; 2018 Aug; 20(1):82. PubMed ID: 30071865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).
    Veitch Z; Zer A; Loong H; Salah S; Masood M; Gupta A; Bradbury PA; Hogg D; Wong A; Kandel R; Charames GS; Abdul Razak AR
    Sci Rep; 2019 May; 9(1):7390. PubMed ID: 31089155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
    Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
    Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
    Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
    Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
    Lheureux S; Tinker A; Clarke B; Ghatage P; Welch S; Weberpals JI; Dhani NC; Butler MO; Tonkin K; Tan Q; Tan DSP; Brooks K; Ramsahai J; Wang L; Pham NA; Shaw PA; Tsao MS; Garg S; Stockley T; Oza AM
    Clin Cancer Res; 2018 Dec; 24(24):6168-6174. PubMed ID: 30108107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.
    Ionkina AA; Tentler JJ; Kim J; Capasso A; Pitts TM; Ryall KA; Howison RR; Kabos P; Sartorius CA; Tan AC; Eckhardt SG; Diamond JR
    Front Oncol; 2017; 7():94. PubMed ID: 28555173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
    Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
    Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
    Matulonis UA; Lee J; Lasonde B; Tew WP; Yehwalashet A; Matei D; Behbakht K; Grothusen J; Fleming G; Lee NK; Arnott J; Bray MR; Fletcher G; Brokx RD; Castonguay V; Mackay H; Sidor CF; Oza AM
    Eur J Cancer; 2013 Jan; 49(1):121-31. PubMed ID: 22921155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
    BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.
    Rayson D; Lupichuk S; Potvin K; Dent S; Shenkier T; Dhesy-Thind S; Ellard SL; Prady C; Salim M; Farmer P; Allo G; Tsao MS; Allan A; Ludkovski O; Bonomi M; Tu D; Hagerman L; Goodwin R; Eisenhauer E; Bradbury P
    Breast Cancer Res Treat; 2016 May; 157(1):109-16. PubMed ID: 27116183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
    Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
    Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
    Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
    Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
    J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action.
    Fletcher GC; Brokx RD; Denny TA; Hembrough TA; Plum SM; Fogler WE; Sidor CF; Bray MR
    Mol Cancer Ther; 2011 Jan; 10(1):126-37. PubMed ID: 21177375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
    Carducci M; Shaheen M; Markman B; Hurvitz S; Mahadevan D; Kotasek D; Goodman OB; Rasmussen E; Chow V; Juan G; Friberg GR; Gamelin E; Vogl FD; Desai J
    Invest New Drugs; 2018 Dec; 36(6):1060-1071. PubMed ID: 29980894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors.
    Chu QS; Bouganim N; Fortier C; Zaknoen S; Stille JR; Kremer JD; Yuen E; Hui YH; de la Peña A; Lithio A; Smith PS; Batist G
    Invest New Drugs; 2021 Aug; 39(4):1001-1010. PubMed ID: 33479856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
    Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
    Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
    Wu S; Zhang L; Li H; Xu J; Jiang C; Sun T
    Trials; 2020 May; 21(1):420. PubMed ID: 32448335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.